



KRAS MUTATIONS


A Crucial Factor in Colorectal Cancer




Colorectal cancer (CRC) is the 2nd leading cause of cancer-related deaths.

2020

147,950 estimated new cases



Inhibiting EGFR signaling is a major treatment option for CRC.



Mutated *KRAS* continuously activates EGFR signaling, which is an important driver of CRC.





36 to 40%

of CRC patients have mutations in the *KRAS* gene.

KRAS mutations in CRC patients block the benefits of anti-EGFR therapy.

AT CODONS OF THE KRAS GENE

DROPLET DIGITAL PCR (ddPCR) PRODUCTS FROM BIO-RAD

- Bio-Rad offers ddPCR KRAS screening kits that can detect the majority of mutations occurring at codons 12, 13, and 61 of the KRAS gene. For research use only
- Screen for other major cancer biomarkers with high sensitivity using a wide range of products from Bio-Rad

Visit bio-rad.com/digital-assays for more information. For research use only.

References

American Cancer Society (2018). Cancer Facts and Figures 2018. cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2018.html, accessed July 6, 2018.

Chan E (2015). KRAS in Colorectal Cancer. My Cancer Genome. mycancergenome.org/content/disease/colorectal-cancer/kras/, accessed July 8, 2015.

American Cancer Society (2020). Colorectal Cancer Facts & Figures 2020-2022. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-figures-2020-2022.pdf

Qing-Hai L, et al. (2020). Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance. https://academic.oup.com/gastro/article/8/3/179/5861161, accessed October 21, 2021.

Bio-Rad, ddPCR, and Droplet Digital PCR are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.

All trademarks used herein are the property of their respective owner.

18-0411 0818